Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

NovaBay to present two poster presentations at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that it will deliver two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA).

15 Oct 2010

Cubist third quarter total net revenues increase 13% to $162.1M

Cubist Pharmaceuticals, Inc. today announced results for the third quarter ended September 30, 2010.

15 Oct 2010

NIH awards two new grants to develop Avidocin platform

AvidBiotics today announced the receipt of two new grants totaling $1 million dollars from the National Institutes of Health that further the development of the company's novel Avidocin™ platform for narrow spectrum antibacterial proteins against important health care threats. These grants add to three previous grants covering AvidBiotics' anti-infectious disease technologies, which provide approximately $3.4 million in currently active funding for the company.

15 Oct 2010

Forum allows healthcare professionals to consider probiotics for patient wellbeing

GPs who have a chance to evaluate the current evidence on probiotics and hear from experts firsthand on their relevance to clinical practice are much more likely to consider them, according to the findings of an interactive debate at the RCGPs Annual Primary Care Conference in Harrogate this week.

14 Oct 2010

Detect-Ready MRSA assay receives first independent validation

Molecular Detection Inc. a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that its Detect-Ready MRSA assay has received its first independent validation in a study conducted at St. George's Healthcare NHS Trust, a leading teaching hospital in the UK.

13 Oct 2010

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

The U.S. Department of Defense has awarded $1.5 million over three years to the Michigan Nanotechnology Institute for Medicine and Biological Sciences and to Ann Arbor-based NanoBio Corporation to develop and test nanoemulsions with potential to fight a wide range of wound infections, including drug-resistant forms.

13 Oct 2010

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed U.S. physicians with regard to their treatment of skin and skin structure infections.

8 Oct 2010

Firm sees drugs sales rising 5 to 7 percent next year, other drug industry news

The Associated Press reports that global prescription drug sales should rise 5 percent to 7 percent next year reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm IMS Health.

8 Oct 2010

First Edition: October 7, 2010

Today's headlines include stories on waivers given some companies that offer only minimal health insurance coverage, insurers' political efforts during this campaign season and efforts in New York to bar the use of food stamps to buy soda.

7 Oct 2010

Vivaglobin therapy effective for patients with primary immunodeficiency

Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.

7 Oct 2010

Paper describes new method for studying bacterial infection of orthopedic implants

A research team, co-headed by Dr. Woo Lee and Dr. Hongjun Wang of Stevens Institute of Technology, has published a paper describing a new method that generates three-dimensional tissue models for studying bacterial infection of orthopedic implants. Dr. Joung-Hyun Lee of Stevens, and Dr. Jeffrey Kaplan of the New Jersey Dental School, are co-authors of the research.

7 Oct 2010

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Progenics Pharmaceuticals, Inc. today announced the award of a grant totaling $4,143,652 from the National Institutes of Health (NIH) for Progenics' program to develop novel monoclonal antibodies to treat Clostridium difficile (C. difficile) infection.

7 Oct 2010

Rochester General Hospital Research Institute awarded $7M for Prevnar 13 study of ear infections in children

The Rochester General Hospital Research Institute has been awarded a $7.1 million grant to study the effectiveness of a new vaccine on the bacteria that cause ear infections in children. Michael E. Pichichero MD, Director of the Research Institute, has been named Principal Investigator of the five year study which will follow children who receive the Prevnar 13 vaccine. The vaccine is manufactured by Pfizer Vaccine Research of Collegeville, Pennsylvania which is funding the grant.

6 Oct 2010

Study on resistance of harmful bacteria to antibiotics

A study by two Florida State University biochemists makes an important contribution to science's understanding of a serious problem causing concern worldwide: the growing resistance of some harmful bacteria to the drugs that were intended to kill them.

6 Oct 2010

SAFC expands fermentation capabilities in Israel facility

SAFC, a member of the Sigma-Aldrich® Group (Nasdaq: SIAL), today announced the completion of its state-of-the-art expansion of its Jerusalem, Israel facility. The additional capacity expands SAFC's contract manufacturing capabilities in large molecule recombinant proteins and small molecule Active Pharmaceutical Ingredients (APIs) through fermentation, including High Potent APIs (HPAPIs) and secondary metabolites.

6 Oct 2010

Health IT may bring unintended consequences

The Philadelphia Inquirer: As the Obama administration nudges the health system toward electronic medical records, researchers have identified some unintended consequences.

6 Oct 2010

Data shows Take Care Clinics’ quality of care exceeds national benchmarks

Take Care Health Systems, a wholly-owned subsidiary of Walgreens and the nation's largest and most comprehensive manager of convenient care clinics and worksite health and wellness centers, today announced that an analysis of de-identified data collected through the company's electronic medical record (EMR) system by the Jefferson School of Population Health showed that the quality of care delivered in Take Care Clinics for treatment of pharyngitis (inflammation of the throat) and upper respiratory infections (URI) meets or exceeds the quality of the care delivered in other settings.

5 Oct 2010

Researchers develop pioneering method to identify lytic enzymes for optimum bacteria killing characteristics

With the worrying rise of antibiotic-resistant superbugs like MRSA, scientists from a wide range of disciplines are teaming up to identify alternative therapies to keep them at bay.

5 Oct 2010

Nasal CPAP machine may cause craniofacial changes

The use of a nasal continuous positive airway pressure (nCPAP) machine for more than 2 years may cause craniofacial changes in adults with obstructive sleep apnea (OSA).

5 Oct 2010

Ceremed awarded NIH SBIR grant to develop soluble carrier for topical delivery of antibiotic Vancomycin

Ceremed, Inc. was awarded a Small Business Innovation Research (SBIR) grant, the company's third in a series of grants from the National Institutes of Health to develop a versatile soluble carrier with bone hemostatic properties for targeted delivery of therapeutic agents directly to surgical sites. The recently awarded grant will aid Ceremed in its effort to develop a soluble carrier to topically deliver the antibiotic Vancomycin.

5 Oct 2010

Antibiotic News and Research

Further Reading

NovaBay to present two poster presentations at IDSA Annual Meeting

Cubist third quarter total net revenues increase 13% to $162.1M

NIH awards two new grants to develop Avidocin platform

Forum allows healthcare professionals to consider probiotics for patient wellbeing

Detect-Ready MRSA assay receives first independent validation

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Firm sees drugs sales rising 5 to 7 percent next year, other drug industry news

First Edition: October 7, 2010

Vivaglobin therapy effective for patients with primary immunodeficiency

Paper describes new method for studying bacterial infection of orthopedic implants

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Rochester General Hospital Research Institute awarded $7M for Prevnar 13 study of ear infections in children

Study on resistance of harmful bacteria to antibiotics

SAFC expands fermentation capabilities in Israel facility

Health IT may bring unintended consequences

Data shows Take Care Clinics’ quality of care exceeds national benchmarks

Researchers develop pioneering method to identify lytic enzymes for optimum bacteria killing characteristics

Nasal CPAP machine may cause craniofacial changes

Ceremed awarded NIH SBIR grant to develop soluble carrier for topical delivery of antibiotic Vancomycin

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News